Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by VictorKonstanon Jul 26, 2012 12:20pm
260 Views
Post# 20155018

Covidien reports Third Quarter results today....

Covidien reports Third Quarter results today....

Check out Covidien Conference Call regarding results...." Pharmaceuticals sales of $501 million in the third quarter were virtually unchanged from last year’s third-quarter sales of $500 million. Operational sales growth in the quarter was 2%, as foreign exchange rate movement reduced the quarterly sales growth rate by two percentage points. Sales of Specialty Pharmaceuticals climbed sharply from those of a year ago, primarily due to the strong performance of the EXALGO® and PENNSAID® products. Sales of Active Pharmaceutical Ingredients were above those of the third quarter of 2011, led by higher sales of narcotics.

Bullboard Posts